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The activity of NK cells depends on the balance of activating and inhibitory signals that are transmitted through respective receptors, including killer immunoglobulin-like receptors (KIRs). HLA class I molecules are ligands for inhibitory KIRs, whereas ligands for their activating counterparts have not been well defined. As well, the physiological role of activating KIRs remains obscure and appears particularly intriguing in view of high degree of diversity with regard to the activating KIR gene content in humans. In general, two major groups of haplotypes may be distinguished: haplotypes A with KIR2DS4 as the only activating KIR and haplotypes B characterized by the presence of at least one activating KIR other than KIR2DS4. Furthermore, various alleles of KIR2DS4 have been described including intact KIR2DS4n001 encoding cell membrane-anchored receptor resembling other activating KIRs and KIR2DS4n003, n005 and n006 (KIR1D) partial deletion variants, encoding protein devoid of transmembrane region and possessing only one immunoglobulin-like domain. 2 The proteins encoded by KIR1D variants are functionally inactive and therefore, a number of individuals homozygous for hapolotype A and KIR1D do not have any activating KIR.
As demonstrated by Verheyden et al., 3, 4 the presence of particular KIRs and their HLA ligands may mediate susceptibility to both myeloid and lymphoid leukemias. The authors first demonstrated higher number of inhibitory KIRs in leukemia patients compared to healthy controls. 3 The subsequent study revealed that negative effect of some inhibitory KIRs depends on simultaneous presence of their HLA ligands. 4 In contrast, no association was found between the genotype of activating receptors and the incidence of leukemia. It must be noted, however, that the authors did not discriminate between the intact KIR2DS4 and KIR1D variants.
The goal of our study was to verify whether the frequency of KIR2DS4 allelic variants differs in patients with leukemia in comparison with healthy subjects. We included 90 adults with chronic myeloid leukemia (CML, n ¼ 31), acute myeloid leukemia ( n ¼ 38), and acute lymphoblastic leukemia (n ¼ 21) who were candidates for allogeneic hematopoietic stem cell transplantation. KIR2DS4n001 and KIR1D alleles were detected according to previously described methodology 5 in patients as well as in their HLA-matched related (n ¼ 31) or unrelated (n ¼ 59) donors, serving as controls. Such selection of control group let us avoid potential bias resulting from the association of HLA genotype with leukemia. All patients and donors were Caucasoids. Patients and sibling donors were of Polish origin, while the majority of unrelated donors were either Polish or German. As previously reported, the distribution of KIR genes among these two populations is very similar. 6 The frequencies of various allele combinations in patients, donors and population controls are listed in Table 1 . The intact KIR2DS4n001 was present in 20% of leukemia patients compared to 33.3% among the donors (P ¼ 0.04). The difference was particularly distinct in a cohort of CML (19.4 vs 45.2%, P ¼ 0.03), while it was not significant in acute myeloid leukemia and acute lymphoblastic leukemia. The physiological role of KIR2DS4 remains unknown and few data are available regarding ligands for this receptor. Katz et al.,
7 demonstrated interaction of KIR2DS4 with HLA class I molecules, which, however, was restricted to HLA-Cw4 and characterized by low affinity. On the other hand, the same group showed that KIR2DS4 may recognize non-HLA class I ligands on melanoma cell lines and on a primary melanoma. 8 That interaction was shown to be both specific and functional and led to the killing of the target cells. In view of those findings, it cannot be excluded that the activating signal mediated by KIR2DS4 may confer susceptibility of other cancers to NK cell-mediated lysis through not yet recognized ligands. Our results strongly support this hypothesis and indicate that CML cells may be a target for KIR2DS4.
KIR1D defective variants of KIR2DS4 are widely distributed among Caucasian populations, but its biological function has not been discovered so far. 6 In our study, the frequency of KIR1D was similar for patients and controls. However, in a setting of CML, the presence of KIR1D in the absence of KIR2DS4n001 was detected significantly more frequently in patients compared to their donors (77.4 vs 51.6%, P ¼ 0.03). Once again, no significant associations were found for acute Table 1 Frequencies of KIR2DS4 and its variant KIR1D among patients with leukemia and their hematopoietic stem cell donors In summary, KIR2DS4 appears to play important role in the regulation of NK cell-mediated immunosurveillance against CML. Further investigation is warranted to determine ligands for this receptor and to verify its association with other diseases. Discrimination between intact KIR2DS4n001 and defective KIR1D variants appears essential in epidemiological studies.
